This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Young, W. F. Search for Related Content PubMed PubMed Citation Articles by Young, W. F., Jr.

Minireview: Primary Aldosteronism—Changing Concepts in Diagnosis and Treatment

Professor of Medicine, Mayo Medical School; Consultant, Division of Endocrinology, Metabolism, Nutrition and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905

Address all correspondence and requests for reprints to: William F. Young, Jr., M.D., Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905. E-mail: Young.William{at}Mayo.edu.

Primary aldosteronism affects 5–13% of patients with hypertension. Patients with hypertension and hypokalemia and most patients with treatment-resistant hypertension should undergo screening for primary aldosteronism with a plasma aldosterone concentration to plasma renin activity ratio. A high plasma aldosterone concentration to plasma renin activity ratio is a positive screening test result, a finding that warrants confirmatory testing. For those patients that want to pursue a surgical cure, the accurate distinction between the subtypes (unilateral vs. bilateral adrenal disease) of primary aldosteronism is a critical step. The subtype evaluation may require one or more tests, the first of which is imaging the adrenal glands with computed tomography, followed by selective use of adrenal venous sampling. Because of the deleterious cardiovascular effects of aldosterone, normalization of circulating aldosterone or aldosterone receptor blockade should be part of the management plan for all patients with primary aldosteronism. Unilateral laparoscopic adrenalectomy is an excellent treatment option for patients with unilateral aldosterone-producing adenoma. Bilateral idiopathic hyperaldosteronism should be treated medically. In addition, aldosterone-producing adenoma patients may be treated medically if the medical treatment includes mineralocorticoid receptor blockade.

This article has been cited by other articles:

				J. M. C. Connell, S. M. MacKenzie, E. M. Freel, R. Fraser, and E. Davies A Lifetime of Aldosterone Excess: Long-Term Consequences of Altered Regulation of Aldosterone Production for Cardiovascular Function Endocr. Rev., April 1, 2008; 29(2): 133 - 154. [Abstract] [Full Text] [PDF]

				P. Mulatero, C. Bertello, D. Rossato, G. Mengozzi, A. Milan, C. Garrone, G. Giraudo, G. Passarino, D. Garabello, A. Verhovez, et al. Roles of Clinical Criteria, Computed Tomography Scan, and Adrenal Vein Sampling in Differential Diagnosis of Primary Aldosteronism Subtypes J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1366 - 1371. [Abstract] [Full Text] [PDF]

				I. Quack, O. Vonend, L. Sellin, J. Stegbauer, G. Dekomien, and L. C. Rump A Tale of Two Patients With Mendelian Hypertension Hypertension, March 1, 2008; 51(3): 609 - 614. [Full Text] [PDF]

				D. Smiley and G. Umpierrez Primary Aldosteronism in Diabetic Subjects With Resistant Hypertension: Response to Ng et al. Diabetes Care, January 1, 2008; 31(1): e3 - e3. [Full Text] [PDF]

				G. Mengozzi, D. Rossato, C. Bertello, C. Garrone, A. Milan, R. Pagni, F. Veglio, and P. Mulatero Rapid Cortisol Assay during Adrenal Vein Sampling in Patients with Primary Aldosteronism Clin. Chem., November 1, 2007; 53(11): 1968 - 1971. [Abstract] [Full Text] [PDF]

				I. Ilias, A. Sahdev, R. H Reznek, A. B Grossman, and K. Pacak The optimal imaging of adrenal tumours: a comparison of different methods Endocr. Relat. Cancer, September 1, 2007; 14(3): 587 - 599. [Abstract] [Full Text] [PDF]

				C. Catena, G. Colussi, E. Nadalini, A. Chiuch, S. Baroselli, R. Lapenna, and L. A. Sechi Relationships of Plasma Renin Levels with Renal Function in Patients with Primary Aldosteronism Clin. J. Am. Soc. Nephrol., July 1, 2007; 2(4): 722 - 731. [Abstract] [Full Text] [PDF]

				G. E. Umpierrez, P. Cantey, D. Smiley, A. Palacio, D. Temponi, K. Luster, and A. Chapman Primary Aldosteronism in Diabetic Subjects With Resistant Hypertension Diabetes Care, July 1, 2007; 30(7): 1699 - 1703. [Abstract] [Full Text] [PDF]

				S. M. Patel, R. K. Lingam, T. I. Beaconsfield, T. L. Tran, and B. Brown Role of Radiology in the Management of Primary Aldosteronism RadioGraphics, July 1, 2007; 27(4): 1145 - 1157. [Abstract] [Full Text] [PDF]

				A. Kazory and I. D. Weiner Primary hyperaldosteronism in a patient with end-stage renal disease Nephrol. Dial. Transplant., March 1, 2007; 22(3): 917 - 919. [Full Text] [PDF]

				C. D Bubbar, D. F Blackburn, M. P Wilson, and T. W Wilson Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Hypertension Due to Primary Aldosteronism: A Case for Exclusion Ann. Pharmacother., January 1, 2007; 41(1): 129 - 132. [Abstract] [Full Text] [PDF]

				D. G. Romero, B. L. Welsh, E. P. Gomez-Sanchez, L. L. Yanes, S. Rilli, and C. E. Gomez-Sanchez Angiotensin II-Mediated Protein Kinase D Activation Stimulates Aldosterone and Cortisol Secretion in H295R Human Adrenocortical Cells Endocrinology, December 1, 2006; 147(12): 6046 - 6055. [Abstract] [Full Text] [PDF]

				F. BEUSCHLEIN and M. REINCKE Adrenocortical Tumorigenesis Ann. N.Y. Acad. Sci., November 1, 2006; 1088(1): 319 - 334. [Abstract] [Full Text] [PDF]

				F. E. Nwariaku, B. S. Miller, R. Auchus, S. Holt, L. Watumull, B. Dolmatch, S. Nesbitt, W. Vongpatanasin, R. Victor, F. Wians, et al. Primary Hyperaldosteronism: Effect of Adrenal Vein Sampling on Surgical Outcome Arch Surg, May 1, 2006; 141(5): 497 - 503. [Abstract] [Full Text] [PDF]

				M. H. Bassett, B. Mayhew, K. Rehman, P. C. White, F. Mantero, G. Arnaldi, P. M. Stewart, I. Bujalska, and W. E. Rainey Expression Profiles for Steroidogenic Enzymes in Adrenocortical Disease J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5446 - 5455. [Abstract] [Full Text] [PDF]

				M J S Langman, R J Lancashire, K K Cheng, and P M Stewart Systemic hypertension and glaucoma: mechanisms in common and co-occurrence Br. J. Ophthalmol., August 1, 2005; 89(8): 960 - 963. [Abstract] [Full Text] [PDF]

				J. M C Connell and E. Davies The new biology of aldosterone J. Endocrinol., July 1, 2005; 186(1): 1 - 20. [Abstract] [Full Text] [PDF]

				R M Reynolds, L A Shakerdi, K Sandhu, A M Wallace, P J Wood, and B R Walker The utility of three different methods for measuring urinary 18-hydroxycortisol in the differential diagnosis of suspected primary hyperaldosteronism Eur. J. Endocrinol., June 1, 2005; 152(6): 903 - 907. [Abstract] [Full Text] [PDF]

				P. Milliez, X. Girerd, P.-F. Plouin, J. Blacher, M. E. Safar, and J.-J. Mourad Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism J. Am. Coll. Cardiol., April 19, 2005; 45(8): 1243 - 1248. [Abstract] [Full Text] [PDF]

				G. L. Schwartz and S. T. Turner Screening for Primary Aldosteronism in Essential Hypertension: Diagnostic Accuracy of the Ratio of Plasma Aldosterone Concentration to Plasma Renin Activity Clin. Chem., February 1, 2005; 51(2): 386 - 394. [Abstract] [Full Text] [PDF]

				F. H. Perschel, R. Schemer, L. Seiler, M. Reincke, J. Deinum, C. Maser-Gluth, D. Mechelhoff, R. Tauber, and S. Diederich Rapid Screening Test for Primary Hyperaldosteronism: Ratio of Plasma Aldosterone to Renin Concentration Determined by Fully Automated Chemiluminescence Immunoassays Clin. Chem., September 1, 2004; 50(9): 1650 - 1655. [Abstract] [Full Text] [PDF]

				R. G. Dluhy and G. H. Williams Aldosterone -- Villain or Bystander? N. Engl. J. Med., July 1, 2004; 351(1): 8 - 10. [Full Text] [PDF]

				M. K. Nishizaka, M. A. Zaman, S. A. Green, K. Y. Renfroe, and D. A. Calhoun Impaired Endothelium-Dependent Flow-Mediated Vasodilation in Hypertensive Subjects With Hyperaldosteronism Circulation, June 15, 2004; 109(23): 2857 - 2861. [Abstract] [Full Text] [PDF]

				H. Oberleithner, T. Ludwig, C. Riethmuller, U. Hillebrand, L. Albermann, C. Schafer, V. Shahin, and H. Schillers Human Endothelium: Target for Aldosterone Hypertension, May 1, 2004; 43(5): 952 - 956. [Abstract] [Full Text] [PDF]

				H. Oberleithner Unorthodox Sites and Modes of Aldosterone Action Physiology, April 1, 2004; 19(2): 51 - 54. [Abstract] [Full Text] [PDF]

				T. L. Goodfriend and D. A. Calhoun Resistant Hypertension, Obesity, Sleep Apnea, and Aldosterone: Theory and Therapy Hypertension, March 1, 2004; 43(3): 518 - 524. [Abstract] [Full Text] [PDF]